Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial
Primary result · Total MACEResult — go to the resultHazard ratio 0.75 95% CI 0.66–0.85Authors' conclusion
Low dose rivaroxaban with aspirin significantly reduces first and total cardiovascular events compared with aspirin alone with a NNT2y of 63 and a 20% net clinical benefit.
Study context
- Population
- Patients with chronic coronary and/or PAD
- Participants
- 27,395 patients
- Comparison
- Rivaroxaban plus aspirin or rivaroxaban alone vs aspirin alone
- Primary endpoint
- Total (first and recurrent) MACE (CV death, stroke or MI)
Methodological detailsexploratory on-treatment and net clinical benefit analyses
- Exploratory on-treatment and net clinical benefit analyses
Primary result
Total MACE
Hazard ratio
0.75
95% CI 0.66–0.85
P < 0.0001
Events by treatment group
Rivaroxaban + aspirin
432
events
Rivaroxaban
508
events
Aspirin
574
events
Rivaroxaban + aspirinvs Aspirin
HR 0.75 (95% CI 0.66–0.85); P < 0.0001
As reported in the abstract
Further findings
| Outcome | HR (95% CI) |
|---|---|
| Net clinical benefitRivaroxaban + aspirin vs Aspirin · 20% higher net clinical benefit · exploratory analysis | 0.80 (16.3%–31.6%) |
Major cardiovascular events (MACE) on vs off randomised treatment
- MACE outcomes similar for those on and off randomised treatment
- On-treatment exploratory analysis
Original publication
Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial. Am Heart J. Published 14 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →